Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors Genovese, M. C., Kremer, J. M., Kartman, C., Schlichting, D. E., Xie, L., Carmack, T., Macias, W. L., Smolen, J. S. WILEY-BLACKWELL. 2015
View details for Web of Science ID 000370860202310